Study on clinical outcomes of viral hepatitis C, mechanism of difficult-to-treat hepatitis C and optimal therapeutic regimens.

Trial Profile

Study on clinical outcomes of viral hepatitis C, mechanism of difficult-to-treat hepatitis C and optimal therapeutic regimens.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Apr 2016

At a glance

  • Drugs Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 May 2012 Planned end date changed from 30 Jun 2010 to 30 Jun 2012 as reported by Chinese Clinical Trial Register.
    • 25 Jul 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top